Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-03-20
2007-03-20
Falk, Anne-Marie (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S023700
Reexamination Certificate
active
09554960
ABSTRACT:
The present invention relates to novel methods and compositions for blocking transmission ofPlasmodium vivaxwhich cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface ofPlasmodium vivaxzygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.
REFERENCES:
patent: WO 89/10936 (1989-11-01), None
patent: WO 94/01552 (1994-01-01), None
patent: WO 94/28930 (1994-12-01), None
patent: WO 95/08631 (1995-03-01), None
patent: WO 95/08631 (1995-03-01), None
patent: WO 98/14472 (1998-04-01), None
McCluskie et al. (1999) Mol. Med. 5:287-300.
Kongkasuriyachi et al. (2004) Vaccine 3205:3213.
Tsuboi et al. (1998) Mol. Med. 12:772-782.
Kofta et al. (2001) Vet Parasitology 100:3-12.
Mendis, Kamini et al.; “Immune modulation of parasite transmission inPlasmodium vivaxmalaria: Anti-gamete antibodies can both block and enhance transmission”;Molecular Strategies of Parasitic Invasion; pp. 417-426, 1987. Alan R. Liss, Inc.
Premawansa, Sunil et al.; “Target antigens of transmission blocking immunity ofPlasmodium vivaxmalaria: Characterization and polymorphism in natural parasite isolates”;J. Immunol. 144 (11):4376-4383 (Jun. 1, 1990).
Snewin, Valerie A. et al.; “Transmission blocking immunity inPlasmodium vivaxmalaria: Antibodies raised against a peptide block parasite development in the mosquito vector”;J. Exp. Med. 181:357-362 (Jan. 1995).
Agabian N., et al., “Molecular strategies of parasitic invasion, ” Alan R. Liss, Inc., (1987), see Mendis, K. et al., “Immune modulation of parasite transmission inPlasmodium vivaxmalaria: Anti-gamete antibodies can both block and enhance transmission”;Molecular Strategies of Parasitic Invasion; pp. 417-426, 1987. Alan R. Liss, Inc.
Premawansa, S. et al., “Target antigens of transmission blocking immunity ofPlasmodium vivaxmalaria: Characterization and polymorphism in natural parasite isolates”;J. Immunol. vol. 144 (11), pp. 4376-4383 (Jun. 1, 1990).
Snewin, V. et al., “Transmission blocking immunity inPlasmodium vivaxmalaria: Antibodies raised against a peptide block parasite development in the mosquito vector”;J. Exp. Med., vol. 181, pp. 357-362 (Jan. 1995).
Kaslow David C.
Torii Motomi
Tsuboi Takafumi
Falk Anne-Marie
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Vaccines for blocking transmission of Plasmodium vivax does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccines for blocking transmission of Plasmodium vivax, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines for blocking transmission of Plasmodium vivax will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3796249